Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043598 | 0.90 | ICMT (0.46) | OPRM1SLC6A3SLC6A4SLC6A2ICMT | |
| SCHEMBL10181623 | 0.83 | OPRM1 (0.40) | OPRM1SLC6A3SLC6A4SLC6A2ICMT | |
| SCHEMBL19262168 | 0.81 | SLC6A3 (0.49) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL29017386 | 0.80 | SLC6A3 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2ICMT | |
| SCHEMBL29017330 | 0.80 | SLC6A3 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2ICMT | |
| SCHEMBL12614285 | 0.80 | SLC6A3 (0.45) | OPRM1SLC6A3SLC6A4SLC6A2ICMT | |
| SCHEMBL14944312 | 0.78 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12002387 | 0.76 | SLC6A3 (0.62) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12542428 | 0.73 | SLC6A3 (0.50) | OPRM1SLC6A3SLC6A4SLC6A2ICMT | |
| SCHEMBL15043683 | 0.73 | SLC6A4 (0.40) | OPRM1SLC6A3SLC6A4SLC6A2ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | OPRM1 744/4885SLC6A3 2766/4885SLC6A4 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.